|Description||HDAC-IN-2, a selective HDAC inhibitor, has been found to probably restrain the transcription and division of tumor oncogene and could also lead to the apoptosis of tumor cells.It is under Phase II trials against Multiple myeloma. IC50: 4 nM and 76 nM for|
|Synonyms||HDAC-IN-2; 2-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-441P620G3P; 441P620G3P; Citarinostat|
|Solubility||DMSO: ≥ 30 mg/mL|
|Application||HDAC-IN-2 is a selective HDAC inhibitor that has been found to probably restrain the transcription and division of tumor oncogene and could also lead to the apoptosis of tumor cells.It is under Phase II trials against Multiple myeloma.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Acetylon Pharmaceuticals|
PCI-34051 is a potent, histone deacetylase 8 (HDAC8)-specific inhibitor with >200-fold selectivity over the other HDAC isoforms. PCI-34051 induces caspase-depen...
Mocetinostat is a rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activi...
HDAC-IN-1, an analogue of MC 1568, is a Iia HDACs inhibitor that could probably influence myogenesis and adipogenesis.
Sirtinol is a SIRT inhibitor. Sirtinol significantly increased the acetylation of p53, which has been reported to be a target of SIRT1/2. Sirtinol significantly...
4SC-202 is an orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic act...
Panobinostat is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), induci...
Chidamide, also known as CS055 and HBI-8000, is an orally bioavailable benzamide type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with p...
Valproic acid sodium salt (Sodium valpro
Valproic acid is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention o...
Oxamflatin, also known as Metacept-3, an aromatic sulfonamide derivative, is a cell-permeable, potent HDAC inhibitor (IC50= 15.7 nM) with antitumor effect.
Resminostat is an orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity. Resminostat binds to and inhibits HDACs ...
Remodelin, a 2-thiazolylhydrazone derivative, is a novel potent and selective inhibitor of the acetyl-transferase protein NAT10, which acetylates both histones ...
TMP195 is a selective class IIa histone deacetylase (HDAC) inhibitor (IC50s= 59 nM, 60 nM, 26 nM and 15 nM for HDAC4, HDAC5, HDAC7 and HDAC9 respectively), and ...
ACY-775 is a selective Histone Deacetylase 6 (HDAC6) inhbiitor with low nanomolar potency and a selectivity of 60- to 1500-fold over class I HDACs. ACY-775 has...
Givinostat (INN) or gavinostat, aslo known as ITF2357, is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic...
LMK-235 is a selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor. LMK-235 demonstrates activity against chemoresistant cancer cell lines in an MTT assa...
Quisinostat, also known as JNJ-26481585, is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potent...
Trichostatin A, also known as TSA, is a HDAC inhibitor. TSA inhibits the eukaryotic cell cycle during the beginning of the growth stage. TSA can be used to alte...
Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM ...
Droxinostat is a selective inhibitor of HDAC3, HDAC6, and HDAC8. Droxinostat shows comparable inhibition of HDAC6 and HDAC8 (IC50 = 2.47 and 1.46 μmol/L, respec...